A multidisciplinary SaveMe project has been launched by the European Union (EU) to develop new nanotechnology-based systems for detection, diagnosis and therapy for cancer. One of the most relevant aspects of the study will be the validation of nanoplatforms in the treatment of cancer of the pancreas.
SaveMe has a budget of EUR13 million ($18.6 million U.S.) -- of which EUR10.5 million ($15 million U.S.) are from the EU which is to last for four years. It is led by the University of Tel Aviv, Tel Aviv, Israel and 20 technological-scientific bodies from nine European countries, two of which are based in the Basque city of Donostia-San Sebastián, Basque Country, Spain: the Centre for Electrochemical Technologies (CIDETEC-IK4) and the Centre for Cooperative Research in Biomaterials (CIC biomaGUNE).
CIDETEC-IK4 is to participate in the SaveMe project in the manufacture of polymeric, nanoparticles syntethised from a single polymer chain. The task of CIC biomaGUNE, is to provide knowledge and their installations in order to generate nanosystems charged with radioisotopes (PET and SPECT) or with contrast agents suitable for undertaking MRI studies and thus evaluating the in vivo behavior and efficacy of the new diagnostic and therapeutic platforms.